頁籤選單縮合
題 名 | The Effect of Fluvastatin on Fibrinolytic Factors in Patients with Hypercholesterolemia=Fluvastatin對高血脂病人纖維溶解因子的影響 |
---|---|
作 者 | 林宗憲; 黃智興; 溫文才; 顏學偉; 賴秀美; 梁馨月; 盧怡旭; 李坤泰; 李智雄; 賴文德; 許勝雄; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 16:12 2000.12[民89.12] |
頁 次 | 頁600-606 |
分類號 | 418.227 |
關鍵詞 | 還原酵素抑制劑; 高血脂; 纖維溶解因子; Fibrinolysis; Statin; Hypercholesterolemia; |
語 文 | 英文(English) |
中文摘要 | 許多研究顯示以HMG-CoA (3-hydro-3methylglutaryl coenzyml A) ,還 原酵素抑制劑治療高血脂對心血管系統有幫忙。然而除了降血脂外還原酵素抑制 劑還有其他藥理作用,由於臨床研究對於HMG-CoA還原酵素抑制劑在纖維蛋白 溶解因子的作用仍然無一致結果,因此以上的好處和纖維蛋白溶解因子間的關係 須要更進一步證實。這篇研究的目的即是要評估Fluvastatin對高血脂病人纖維溶 解因子的影響。在食用6週低脂低膽固醇飲食後23位已知原發性高膽固醇血症 伴隨低密度膽固醇超過130mg/dl及至少有2個以上危險因子或空腹低密度膽固 醇超過160mg/dl病人選擇進入此研究。在實驗初及服用40毫克Fluvastatin 8周 後各抽靜脈血來分析組織漿胞素原活化劑(t-PA),漿胞素原活化劑之抑制劑 (PAI-1),纖維原(fibrinogen),D雙體(D-dimer)及血脂。在8周治療後 Fluva-statin 降低11%膽固醇(261.9 mg/dl vs 223.2 mg/dl, P<0.01)及低密度膽固醇22% (191.9 mg/dl vs 149.3 mg/dl, P<0.01)。D雙體明顯下降 (0.38 ng/L vs 0.28 ng/L, P=0.02) 和組織漿胞素原活化劑,漿胞素原活化劑之抑制劑及纖維原有下降傾向。 Fluvastatin 改善纖維溶解因子。這結果也許可部份解釋HMG-CoA還原酵素抑制 劑除了降血脂外還透過其他有利機轉助益心血管系統。 |
英文摘要 | Several studies have shown cardiovascular benefit in treating hypercholesterolemia with HMG-CoA reductase inhibitor. However, in addition to the lowering of cholesterol, the beneficial effects of this inhibitor reflect other pharmacological activities. Whether these beneficial effects are partly mediated by changes in fibrinolytic factors remains to be proven, since clinical studies on the effects of HMG-CoA reductase inhibitors on fibrinolytic factors have not yielded consistent results. The purpose of this study was to evaluate the effects of fluvastatin on fibrinolytic factors in hypercholesterolemic patients. After 6 weeks on a low-fat, low-cholesterol diet, 23 outpatients known to have primary hypercholesterolemia with low density lipoprotein cholesterol (LDL-C) ≧ 130 mg/dl with at least 2 risk factors or fasting LDL-C≧160 mg/dl were selected for the study. Venous blood samples were collected at baseline and at 8 weeks after fluvastatin therapy (40 mg/day) to measure of tissue plasminogen activator (t-PA), plasminogen activators inhibitor-1 (PAI-1), fibrinogen, D-dimer and lipid profile. After 8 weeks of therapy, fluvastatin reduced serum cholesterol by 11% (261.9 mg/dl vs 233.2 mg/dl, P<0.01) and LDL-C by 22% (191.9 mg/dl vs 149.3 mg/dl, P<0.01). D-dimer was significantly decreased (0.38 ng/L vs 0.28 ng/L, P=0.02) and tPA, PAI-1 and fibrinogen tended to decrease after therapy. Fluvastatin therapy improved fibrinolytic profile; the result of this study may in part explain the benefit of HMG-CoA reductase inhibitor on cardiovascular system other than lipid lowering. |
本系統中英文摘要資訊取自各篇刊載內容。